Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCP1401 in Stage 2 Hypertension
NCT02916602Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Amosartan Plus in hypertension (HTN) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change from baseline in sitting systolic blood pressure at 8 weeks. Started Apr 2015; status: completed.
02
Drugs
Amosartan Plus
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02916602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916602.